ATM、BRCA1、BRCA2、CHEK2和PALB2胚系致病变异携带者的对侧乳腺癌风险
基于CARRIERS研究中15104例接受同侧手术的浸润性乳腺癌女性,评估ATM、BRCA1、BRCA2、CHEK2和PALB2胚系致病变异携带者对侧乳腺癌风险。BRCA1、BRCA2和CHEK2致病变异携带者对侧乳腺癌风险显著升高(风险比>1.9),PALB2致病变异合并ER阴性乳腺癌者风险亦升高(风险比2.9),而ATM致病变异携带者风险未见显著增加。
要点
- BRCA1、BRCA2和CHEK2致病变异携带者对侧乳腺癌风险显著升高,风险比>1.9。
- PALB2致病变异合并ER阴性乳腺癌者对侧乳腺癌风险升高,风险比2.9。
- ATM致病变异携带者对侧乳腺癌风险未见显著增加。
核心结论
- 已知携带BRCA1、BRCA2、CHEK2或PALB2胚系致病变异的乳腺癌女性对侧乳腺癌风险显著增加,可能从加强监测和风险降低策略中获益。
研究设计与样本
- CARRIERS研究前瞻性随访的15104例接受同侧手术的浸润性乳腺癌女性,采用多变量比例风险回归分析,考虑死亡竞争风险并调整患者和肿瘤特征,比较各基因致病变异携带者与无致病变异者的对侧乳腺癌风险。
主要发现
- BRCA1、BRCA2和CHEK2致病变异携带者对侧乳腺癌风险显著升高(风险比>1.9),仅PALB2致病变异合并ER阴性乳腺癌者风险升高(风险比2.9),ATM致病变异携带者风险未见显著增加。
- 非洲裔美国致病变异携带者与非西班牙裔白人致病变异携带者对侧乳腺癌风险升高程度相似。
- 绝经前致病变异携带者10年对侧乳腺癌累积发病率:BRCA1为33%,BRCA2为27%,CHEK2为13%,PALB2合并ER阴性乳腺癌为35%。
- 绝经后致病变异携带者10年对侧乳腺癌累积发病率:BRCA1为12%,BRCA2为9%,CHEK2为4%。
关键数值与推荐
- BRCA1、BRCA2、CHEK2致病变异携带者对侧乳腺癌风险比>1.9。
- PALB2致病变异合并ER阴性乳腺癌者对侧乳腺癌风险比2.9。
- 绝经前BRCA1致病变异携带者10年累积发病率33%。
- 绝经前BRCA2致病变异携带者10年累积发病率27%。
- 绝经前CHEK2致病变异携带者10年累积发病率13%。
临床怎么用
- 作者认为已知携带BRCA1、BRCA2、CHEK2或PALB2胚系致病变异的乳腺癌女性可能从加强监测和风险降低策略中获益。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To estimate the risk of contralateral breast cancer (CBC) among women with germline pathogenic variants (PVs) in ATM, BRCA1, BRCA2, CHEK2, and PALB2. METHODS: The study population included 15,104 prospectively followed women within the CARRIERS study treated with ipsilateral surgery for invasive breast cancer. The risk of CBC was estimated for PV carriers in each gene compared with women without PVs in a multivariate proportional hazard regression analysis accounting for the competing risk of death and adjusting for patient and tumor characteristics. The primary analyses focused on the overall cohort and on women from the general population. Secondary analyses examined associations by race/ethnicity, age at primary breast cancer diagnosis, menopausal status, and tumor estrogen receptor (ER) status. RESULTS: Germline BRCA1, BRCA2, and CHEK2 PV carriers with breast cancer were at significantly elevated risk (hazard ratio > 1.9) of CBC, whereas only the PALB2 PV carriers with ER-negative breast cancer had elevated risks (hazard ratio, 2.9). By contrast, ATM PV carriers did not have significantly increased CBC risks. African American PV carriers had similarly elevated risks of CBC as non-Hispanic White PV carriers. Among premenopausal women, the 10-year cumulative incidence of CBC was estimated to be 33% for BRCA1, 27% for BRCA2, and 13% for CHEK2 PV carriers with breast cancer and 35% for PALB2 PV carriers with ER-negative breast cancer. The 10-year cumulative incidence of CBC among postmenopausal PV carriers was 12% for BRCA1, 9% for BRCA2, and 4% for CHEK2. CONCLUSION: Women diagnosed with breast cancer and known to carry germline PVs in BRCA1, BRCA2, CHEK2, or PALB2 are at substantially increased risk of CBC and may benefit from enhanced surveillance and risk reduction strategies.
引用
- Yadav S, Boddicker NJ, Na J, et al. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. J Clin Oncol. 2023. PMID: 36623243. doi:10.1200/JCO.22.01239
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。